Analysis
Biotech startup investment held steady through 2026 even as artificial intelligence absorbed the marginal venture dollar in nearly every other category, Crunchbase News reported.
- Global biotech funding range -- tracking inside its recent $36 billion to $40 billion annual band
- AI-focused biotech funding, 2026 -- more than $6 billion of that total
The largest rounds of the year show where the money concentrated:
“- Earendil Labs -- $787 million: Delaware-registered, working on AI-designed protein therapeutics.”
- Isomorphic Labs -- $2.1 billion Series B: the Alphabet-spun AI drug design company in London, built on DeepMind's structure-prediction work. Competitors: Recursion, Insilico Medicine.
- Earendil Labs -- $787 million: Delaware-registered, working on AI-designed protein therapeutics.
- NewLimit -- $435 million Series C: South San Francisco longevity company focused on epigenetic reprogramming, co-founded by Coinbase CEO Brian Armstrong.
- Chai Discovery -- $400 million Series C: San Francisco AI drug discovery lab, which Pulse covered in July.
Exits ran on two tracks. At least 12 venture-funded companies sold for $1 billion or more. The IPO path reopened for clinical-stage assets: Kailera Therapeutics listed in April, only six months after its Series B and two years after being founded in 2024; Kardigan brought its personalized medicine platform to Nasdaq in June on the back of more than $550 million raised in the prior year; and Latigo Biotherapeutics, a pain company, priced in August. Parabilis Medicines raised a Series F in January rather than testing the window.
The structural fact underneath the totals is that more than half of all biotech investment, and most of the rounds, remain seed and early stage. That is the opposite of the AI market, where the dollar-weighted center has migrated to growth and pre-IPO rounds at $10 billion-plus marks. Biotech's capital is dispersed across many small bets with binary scientific outcomes; AI's is concentrated in a handful of enormous ones with correlated outcomes.
The pharma bid is the load-bearing assumption underneath all of it. Large-cap pharmaceutical companies face a concentrated patent cliff through the late 2020s -- Merck's Keytruda, Bristol Myers Squibb's Eliquis and others -- and have publicly committed to filling the gap with acquisitions rather than internal discovery. That is what produced the 12-plus billion-dollar exits and what sustains entry valuations at the seed stage. If rate pressure or political action on drug pricing compresses pharma balance sheets, the acquirer of last resort weakens and the whole early-stage price structure moves with it.
The caution for LPs: "held steady" in nominal dollars is a decline in real terms against a 2026 cost base, and the $6 billion AI-biotech slice is doing a lot of work in the headline. Strip Isomorphic's $2.1 billion out and the AI-native share looks a good deal thinner. The reopened IPO window is also narrow -- three named listings across five months is a window, not a market.
